Locations:
Search
One sequence/combo = longer survival, lower costs
New mRCC medication regimen effective and well tolerated
Drug stimulates an immune response to survivin
Many genetic alterations were related to other malignancies
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Phase 1b trial shows good response rate
Individual tumor DNA may be key
Cleveland Clinic urologist performs first procedure in Europe
Response to larotrectinib “almost miraculous”
Please join our staff as we participate or present in the following oral and poster presentations at the 2018 ASCO Annual Meeting
Established lymphoma/leukemia therapy also targets glioma stem cells
Advertisement
Advertisement